Introduction
The activation of epidermal growth factor receptor (EGFR) and its downstream signaling pathways are important to the survival and proliferation of non-small cell lung cancer (NSCLC; ref. 1). To date, several EGFR mutations have been discovered in NSCLC (2) , which are associated with the therapeutic response to EGFR tyrosine kinase inhibitors (TKI; refs. [3] [4] [5] . The most frequent EGFR mutations are L858R and deletions in exon 19 (6) (7) (8) . For advanced NSCLC with sensitizing EGFR mutations, randomized controlled studies have shown that the progression-free survival (PFS) under first-line gefitinib or erlotinib treatment was longer than PFS under platinum-based chemotherapy (9) (10) (11) (12) . Thus, EGFR TKI has become an important therapeutic option for advanced NSCLC.
Several deletions in exon 19 have been found in NSCLC. Most of these deletions encompass the amino acids from codons L747 to E749 (LRE fragment; ref. 13) , while other deletions do not involve any of the LRE fragment. According to the Somatic Mutations in EGFR Database (SM-EGFR-DB; ref. 14) , the most frequent deletions in exon 19 of EGFR were delE746-A750 (66.1%), followed by delL747-P753insS (56.8%), delL747-A750insP (4.0%), and delL747-T751 (3.7%). In addition, the most common non-LRE deletion was delS752-I759. Structural analyses showed allosteric mechanism important for EGFR kinase domain activation (15) . The deletions in EGFR exon 19, located between strand b3 and helix aC, could disrupt inactive conformation of EGFR kinase domain and enhance the effectiveness of EGFR TKIs (15) (16) (17) (18) . Although previous study has shown that the outcome of patients with NSCLCs under erlotinib treatment was not affected by the number of amino acids deleted (19) , different response rates (RR) to EGFR TKIs, ranging from 70% to 100%, were observed in NSCLC, with deletions in exon 19 occurring at different amino acid positions, such as deletions from E746 or from L747, and deletions not encompassing the entire LRE fragment (14) . Therefore, deletions involving different amino acid fragments in exon 19 might be associated with different clinical outcome in patients with NSCLC under EGFR TKIs.
This study was conducted to investigate whether deletions in EGFR exon 19 occurring at different amino acid positions in advanced NSCLC are associated with different therapeutic responses and clinical outcomes during EGFR TKI treatment. Whether the size of the deletion in EGFR exon 19 associated with different clinical outcome were reevaluated in advanced NSCLC under EGFR TKI treatment.
Materials and Methods

Study population
In this retrospective study, consecutive patients who were diagnosed with NSCLC between January 2004 and June 2010 in the National Taiwan University Hospital were identified. Tumor specimens were obtained by surgical or needle biopsy and included primary lung tumors, malignant pleural effusion cell blocks, and distant metastases. The lung cancer histology was classified according to the World Health Organization (Geneva, Switzerland) pathology classification system (20) . The extent of disease was evaluated by computed tomography (CT) scans of the chest (from neck to adrenal glands) and brain, and bone scans. Clinical stages were determined according to the seventh edition of the American Joint Committee on Cancer (AJCC; ref. 21) . The clinical characteristics of enrolled patients were recorded, including age, gender, smoking history, weight loss (!5%) on presentation, and Eastern Cooperative Oncology Group (ECOG) performance status. Informed consent was obtained from each subject, and the study protocol was approved by the International Review Board of the National Taiwan University Hospital (IRB number: 201107010RC).
EGFR mutation analysis
The process for mutation analysis of the EGFR gene was described previously (22) (23) (24) . Briefly, DNA was extracted from tumors embedded in paraffin blocks by a QIAmp DNA Mini kit (QIAGEN). The tyrosine kinase domains of EGFR (exons 18-21) were amplified by PCR. RNA was extracted from frozen tumor specimens using RNeasy Mini Kit (QIA-GEN). Reverse transcriptase PCR was used to amplify the 4 exons (exons 18-21) of the tyrosine kinase domain of the EGFR gene, with forward and reverse primers as 5 0 -GGATCGGCCTCTTCATGC-3 0 and 5 0 -TAAAATTGATTC-CAATGCCATCC-3 0 , respectively (21) . The amplicons were then sequenced on an automatic ABI PRISM 3700 DNA analyzer (Applied Biosystems). All sequencing reactions were carried out in both forward and reverse directions using tracings from at least 2 PCRs.
EGFR TKI treatment for NSCLC
Advanced NSCLC was defined as stage IV or postoperative recurrence. We identified advanced NSCLC patients who had received EGFR TKIs (including gefitinib and erlotinib) for treatment. Patients were excluded for further analysis if they received EGFR TKIs as maintenance therapy or in combination with chemotherapy. The final selected patients constituted the population for investigating the therapeutic response and clinical outcome in NSCLCs with deletions in exon 19 occurring at different amino acid positions or of different sizes. Chest radiographs were carried out every 2 to 3 weeks and chest CT scans every 2 to 3 months to evaluate treatment response and disease progression. The best overall response to EGFR TKI was determined according to the Response Evaluation Criteria in Solid Tumors Group (RECIST, version 1.0; ref. 25) . PFS was defined as the length of time from the first day of TKI treatment until disease progression or death. Overall survival (OS) was defined as the length of time from the first day of cancer treatment until death or the last follow-up on May 31, 2011.
Statistical analysis
To investigate whether deletions in exon 19 occurring at different amino acid positions were associated with different therapeutic responses and clinical outcomes during EGFR TKI treatment, patients were categorized according to exon 19 deletions: encompassing the entire LRE fragment (LRE group) or not encompassing the entire LRE fragment (non-LRE group). In the LRE group, patients were further divided according to the deletion starting codon: from E746 (DE746 group) or from L747 (DL747 group). On the other hand, we also evaluated whether different number of nucleotides or amino acids deleted in exon 19 was associated with different clinical outcomes in NSCLC under EGFR TKI treatment, as the study by Taron and colleagues (19 
Translational Relevance
The most frequent mutations observed in the epidermal growth factor gene (EGFR) in non-small cell lung cancer (NSCLC) are L858R and deletions in exon 19, both of which are sensitive to EGFR tyrosine kinase inhibitor (TKI) treatment. However, it is unclear whether different deletions in exon 19 are associated with different therapeutic response and clinical outcomes under EGFR TKI treatment. We found that the therapeutic response associated with EGFR TKI treatment was different among NSCLC patients with deletions in exon 19 occurring at different amino acid positions, and patients with non-LRE deletions had the least response. NSCLC patients with non-LRE deletions also had relatively short PFS, though not significantly different to that in patients with LRE deletions. The results indicate that the expected clinical outcome under EGFR TKIs depends on not only the existence but also the types of deletions in exon 19. deletions in exon 19. OS and PFS between different stratified patient groups were evaluated by the Kaplan-Meier curve with log-rank tests. Multivariate analyses for OS and PFS were conducted using the Cox proportional hazard model. In addition to deletions in exon 19, other covariates included in the models were age (!70 vs. <70 years), gender, history of smoking, ECOG performance status (!2 vs. <2), weight loss (!5%) on presentation, disease stage (stage IV vs. postoperative recurrence), extent of disease (number of metastases !2 vs. <2), cancer histology (adenocarcinoma vs. nonadenocarcinoma), and the clinical setting of EGFR TKI treatment (first line, second line, third line, or subsequent line). Backward variable selection was carried out with significance for entry and stay set at 0.10. A 2-sided P < 0.05 was considered statistically significant. All statistical analyses were conducted with SPSS software (version 17.0 for Windows).
Results
Deletions in EGFR exon 19 occurring at different amino acid positions
From January 2004 to June 2010, 1,607 NSCLC patients were examined for EGFR mutations. Deletions in exon 19 of EGFR were detected in 308 patients, who constituted the study population ( Table 1 ). The entire LRE fragment was involved in 298 deletions (96.7%). The most frequent 
deletions in exon 19 were delE746-A750 (65.9%), followed by delL747-P753insS (8.1%) and L747-T751 (5.8%). The clinical characteristics of the study population are presented in Table 2 . The mean patient age was 61.4 years (range, 27-95). Most of the patients were female (57.1%) and never-smokers (76%). Adenocarcinoma was the principal histology observed (94.5%). Ten patients (3.2%) constituted the non-LRE group (Table 3) . The most common non-LRE deletion was delS752-I759 (40% of the non-LRE group). The mean age of these patients was 61.4 years (range, 43-95 years), and most patients were female (60%) and never-smokers (70%). All 10 non-LRE patients had adenocarcinoma.
Within the study population, 210 patients had received EGFR TKIs for advanced NSCLC. Six patients received EGFR TKIs as maintenance therapy or in combination with chemotherapy and were excluded from further analyses. The remaining 204 patients constituted the patient group for investigating therapeutic response and clinical outcomes in NSCLC patients who had deletions in exon 19 occurring at different amino acid positions and who were treated with EGFR TKIs. The clinical characteristics of these patients are summarized in Supplementary Table SA2 . EGFR TKIs were used as first-line treatment in 114 patients (55.9%). Gefitinib was the principal EGFR TKI used by the patients (66.2%). The overall RR to EGFR TKIs was 70.1%.
Of the LRE patients (n ¼ 197), 148 were in the DE746 group and 49 were in the DL747 group. More patients in the DE746 group had adenocarcinoma compared with patients in the DL747 group (97.3% vs. 87.8%, P ¼ 0.026). Gefitinib was used in 63.5% of the DE746 patients and in 69.4% of the DL747 patients (P ¼ 0.455). Other clinical characteristics did not differ significantly between the 2 groups. Seven patients were in the non-LRE group (Table 3) . The RRs to EGFR TKIs were 68.2% and 79.6% in the DE746 and DL747 groups, respectively ( Table 4 ). The RR was also evaluated in subgroups of DE746 and DL747. In the DE746 group, the RR of NSCLC with delE746-A750 was 67.9%. In the DL747 group, the RRs of NSCLCs with delL747-P753insS, delL747-T751, and delL747-S752 were 76.9%, 70.0%, and 88.9%, respectively. Compared with patients in the DL747 group, the DE746 patients displayed a lower RR to EGFR TKI (adjusted OR, 0.265; P ¼ 0.011). Patients in the non-LRE Abbreviation: NSCLC-NOS, NSCLC-not otherwise specified. a Including squamous cell carcinoma (n ¼ 6), adenosquamous cell carcinoma (n ¼ 1), and lymphoepithelioma-like carcinoma (n ¼ 1). The median PFS time associated with EGFR TKI treatment was 9.8 months (95% CI, 8.2-11.4 months). The median PFS was 9.8 months (95% CI, 7.9-11.7 months) for patients in the DE746 group and 10.5 months (95% CI, 7.7-13.3 months) for DL747 patients. The median PFS did not differ between patient subgroups with DE746 deletion or DL747 deletion ( Supplementary Fig. S1A and S1B) . Although the non-LRE patients showed the shortest median PFS of 5.9 months (95% CI, 3.9-7.8 months), the difference was not statistically significant either compared with DE746 or DL747 patients (P ¼ 0.665, Fig. 1A ). Comparing non-LRE group with the entire LRE group, the median PFS was also not statistically different (P ¼ 0.398). Multivariate analyses on PFS indicated that the only significant factors for PFS were disease stage, extent of disease, and cancer histology ( Table 5 ). The median OS associated with EGFR TKI treatment was 33.1 months (95% CI, 27.8-38.5 months). Patients with DE746, DL747, or non-LRE deletions did not have different median OS (P ¼ 0.776, Fig. 1B ). In addition, patient subgroups with DE746 or DL747 deletions did not have significant median OS ( Supplementary Fig. S1C and S1D). Multivariate analysis on OS indicated that ECOG performance status, extent of disease, and cancer histology were the only significant factors (Table 5) .
Deletions in EGFR exon 19 of different sizes
In the 308 patients with deletions in exon 19 of EGFR, the number of nucleotides deleted in exon 19 ranged from 9 to 27 and the most frequent number was 15 (233 patients, 75.6%). The numbers of amino acid deleted in exon 19 ranged from 3 to 9, and the most frequent number was 5 (230 patients, 74.7%). The response and survival to EGFR TKI treatment was evaluated in advanced NSCLC patients with deletions in EGFR exon 19 of different nucleotide or amino acid sizes. In the 204 patients who received EGFR TKIs, 156 patients (76.5%) had 15 nucleotides deleted in exon 19 of EGFR. The clinical characteristics were not significantly different between patients with deletion of 15 nucleotides and those with deletion of less or more than 15 nucleotides (Supplementary Table SA3 ). The RR, PFS, and OS between 2 patient groups were also not statistically different (P ¼ 0.229, 0.949, and 0.758, respectively; Supplementary Fig. S2A and S2B ). On the other hand, patients who received EGFR TKI treatment were categorized into 4 groups according to the numbers of amino acid deleted in exon 19: 5 amino acids in 154 patients (75.5%), 6 amino acids in 14 patients (6.9%), 7 amino acids in 20 patients (9.8%), and other numbers of amino acid in 16 patients (7.8%) (Supplementary Table SA4 ). The RRs to EGFR TKIs were not significantly different between the 4 groups, ranging from 62.5% to 85% (P ¼ 0.370, by univariate logistic regression analysis). The PFS (Supplementary Fig. S3A ) and OS under EGFR TKIs (Supplementary Fig. S3B ) were not significantly different between 4 groups (P ¼ 0.794 and 0.946 by log-rank test, respectively).
Discussion
In this study, we observed that deletions in exon 19 of EGFR not encompassing the entire LRE fragment were uncommon. We found the most frequent deletions were delE746-A750 (65.5%), delL747-P753insS (8.1%), and delL747-T751 (5.8%), as the results from COSMIC database (2) . The therapeutic response associated with EGFR TKI treatment was different among NSCLC patients with deletions in exon 19 occurring at different amino acid positions. Patients with non-LRE deletions in exon 19 showed a worse response to EGFR TKIs than those with LRE deletions. However, the clinical outcomes, including PFS and OS, were not statistically different in NSCLC patients with deletions in EGFR exon 19 occurring at different amino acid positions. We found the average RR in DE746 group would be lower than that in DL747 group, as the results from SM-EGFR-DB (14) . Furthermore, we also found non-LRE deletions associated with lower RR under EGFR TKIs, compared with LRE deletions. The activation of EGFR kinase domain is regulated by complex allosteric mechanism (15) (16) (17) (18) . The inactive conformation of EGFR kinase domain needs the loop between strand b3 and helix aC packing against L858 and L861 on the activating loop, and disruption of the inactive conformation enhances the compatibility of erlotinib with the EGFR kinase domain (15) . In addition, one recent study also showed that a new class of EGFR mutation, exon 19 insertions, is associated with sensitivity to EGFR TKI (26) . All the identified exon 19 insertions result in substitution for L747 with a proline residue. The authors did structural analysis and found L747 was a key hydrophobic core stabilizing the inactive form of EGFR, and the substitution was predicted to disrupt the hydrophobic core and favored the active conformation of EGFR. Therefore, our results are consistent with previous studies and suggest the biological importance of the LRE residues in sensitivity to EGFR TKI in NSCLC. Further crystallographic studies would be needed to evaluate whether deletions in exon 19 occurring at different amino acid positions cause different conformation changes in EGFR kinase domain and are associated with different sensitivity to EGFR TKI.
The RR associated with gefitinib or erlotinib in NSCLC with sensitizing EGFR mutations ranges from 54.5% to 83% and the median PFS ranges from 9.2 months to 13.1 months (9) (10) (11) (12) . Different RR to EGFR TKIs in these studies might be due to different frequencies of activating EGFR mutations in the study populations. Previous studies showed L858R mutation was associated with relatively lower RR than deletion in exon 19 (10, 27, 28) . In addition, our results also showed deletions in exon 19 occurring at different amino acid positions were associated with different RR. In patients with advanced NSCLC under EGFR TKIs, the RR to EGFR TKIs correlate with the length of median PFS (29) . However, at least 14% increase of RR was needed to prolong median PFS by 1 month. Consequently, the population size needed to detect differences in median PFS would be larger than that to detect differences of RR. This could be one reason why several studies did not show different median PFS under EGFR TKIs between NSCLC with L858R mutation and that with deletion in exon 19 (9) (10) (11) . Furthermore, although non-LRE deletions were associated with shorter median PFS than LRE deletions in this study, the population size of non-LRE group is small and would not have adequate power for the differences in median PFS to be detected. Further studies would be required to evaluate whether NSCLC patients with non-LRE deletions in exon 19 have shorter median PFS than those with LRE deletions.
Several techniques were developed to screen for EGFR mutations in NSCLC patients (30) . With some techniques, including direct sequencing and fragment length analysis, detection of all deletions in exon 19 is possible. Other techniques, such as smart amplification process, detect only specific deletions in exon 19 and may miss uncommon non-LRE deletions (30) (31) (32) . Our results show NSCLC patients with non-LRE deletions could have lower RR and relative short median PFS compared with those with LRE deletions. Therefore, techniques which detect all deletions in exon 19 would provide more clinical information. However, it is unknown whether detection of all uncommon non-LRE deletions in exon 19 is cost effective, and studies are needed to determine the most ideal method for detecting deletions in exon 19 of EGFR.
Some limitations of this study should be concerned. First, this is an observational study and there is no clear biological explanation about the different RRs of EGFR TKI in exon 19 deletions occurring at different amino acid positions. In vitro analyses, using EGFR TKIs to treat transfected cell lines harboring EGFR exon 19 deletions occurring at different amino acid positions, will be valuable to understand how these deletions affect sensitivity to EGFR TKIs. Furthermore, crystal structural analysis of the different exon 19 deletions may also disclose the different structural effects on the EGFR activation and response to EGFR TKIs. Second, this is a retrospective study and thus, could contain selection bias. We found that more patients in the DE746 group had adenocarcinoma compared with the DL747 group. However, this confounding factor was adjusted during analysis for the RR. As a result, the differences in response among NSCLC patients with deletions occurring at different amino acid positions were independent of cancer histology. Finally, none of our patients with LRE deletions in exon 19 of EGFR had deletions starting at codon I744 or K745. Therefore, our results do not clarify the response and clinical outcomes associated with EGFR TKI treatment in NSCLC patients with deletions starting at codon I744 or K745. Additional studies are required to determine the sensitivity to EGFR TKIs in NSCLC patients with DI744 or DK745 deletions.
In conclusion, this study highlights the frequency and distribution of deletions in exon 19 of EGFR in NSCLC patients. We found that the response associated with EGFR TKI treatment may be different among NSCLC patients with deletions occurring at different amino acid positions and patients with non-LRE deletions had the least response. NSCLC patients with non-LRE deletions also had relatively short PFS, though not significantly different to that in patients with LRE deletions. Therefore, this study showed that, in advanced NSCLC patients, the expected clinical outcome under EGFR TKIs depends on not only the existence but also the types of deletions in exon 19. 
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